



Patitioner's Docket No. MPI01-021P1RNM

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re application of: Glucksmann, Maria A.

Application No.: 10/085,233

Group No.: 1645

Filed: February 28, 2002

Examiner: N/A

For: 93870, A HUMAN G-PROTEIN COUPLED RECEPTOR AND USES THEREFOR

**Assistant Commissioner for Patents**

**Washington, D.C. 20231**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**List of Sections Forming Part of This Supplemental Information Disclosure Statement**

The following sections are being submitted for this Supplemental Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Form PTO/SB/08A (substitute for Form PTO-1449)
3. ☒ Copies of Listed Information Items Accompanying This Statement
4. ☒ Copy of International Search Report.

**RECEIVED**  
APR 21 2003  
TECH CENTER 1600/2900

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- ☒ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Address" Mailing Label No.

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

*Simonne Corriveau*  
Simonne Corriveau

(type or print name of person certifying)

Date April 15, 2003

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

### **Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this supplemental information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.


### **Copies of Listed Information Items Accompanying This Statement**

Legible copies of all items listed in Form PTO/SB/08A (substitute for Form PTO-1449) accompany this information statement.

April 15, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By



Tracy M. Sioussat

Registration No. 50,609

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-374-7679

Facsimile - 617-551-8820



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet

1

of

1

**Complete if Known****Application Number**

10/085,233

**Filing Dat**

February 28, 2002

First Name and Inventor

Glucksmann, Maria A.

Group Art Unit

1645

Examiner Name

	N/A
--	-----

Attorney Docket Number

**MPI01-021P1RNM**

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.